Longwood Area Diabetes/Metabolism Research Seminar Series
DF/HCC Calendar
Thyme 1.3
© 2006 eXtrovert Software LLC. All rights reserved.
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT)
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT)
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT)
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT
March 23-25, 2008
San Diego, CA
Sponsored by
The National Cancer Institute
Kellogg Health Scholars Program
Co-Chairs:
Karen Emmons, Ph.D., Harvard School of Public Health
Eliseo Pérez-Stable, M.D., University of California at San Francisco
Topics to be Covered:
• Behavioral Intervention Design
• Mixed Research Methods
• Longitudinal Research Designs
• Mediation Analysis
• Measurement Issues: Race/Ethnicity and SES
• Multi-Level Statistical Methods
• Behavioral Genetics Methods
To be eligible to participate, you must:
• Be from a racial/ethnic minority group, from a disadvantaged/underserved group, and/or have a disability,
• Be an investigator at an early or mid-career level (e.g., post-doctoral fellow, research associate, assistant professor, associate professor),
• Have interests in Behavioral Science and Cancer-Related Research (e.g., tobacco cessation, obesity, physical activity, diet/nutrition, cancer screening, sun safety, cancer decision making, coping with cancer, cancer survivorship)
• Have not been a PI on a National Institutes of Health R01 funded grant,
• Reside in the United States or U.S. territory, and
• Submit an application with supporting documents
Application Deadline: October 29, 2007, 5:00pm (Eastern Time)
Applications can be obtained at: http://www.scgcorp.com/B_methods/
Note: Twenty-five participants will be selected. Travel and lodging will be sponsored by NCI only for participants who live and work 50 miles or more outside of San Diego, California.
For additional information, contact:
Ms. Debbie Libbey
e-mail: b-methods@scgcorp.com
phone: 301-670-4990
March 23-25, 2008
San Diego, CA
Sponsored by
The National Cancer Institute
Kellogg Health Scholars Program
Co-Chairs:
Karen Emmons, Ph.D., Harvard School of Public Health
Eliseo Pérez-Stable, M.D., University of California at San Francisco
Topics to be Covered:
• Behavioral Intervention Design
• Mixed Research Methods
• Longitudinal Research Designs
• Mediation Analysis
• Measurement Issues: Race/Ethnicity and SES
• Multi-Level Statistical Methods
• Behavioral Genetics Methods
To be eligible to participate, you must:
• Be from a racial/ethnic minority group, from a disadvantaged/underserved group, and/or have a disability,
• Be an investigator at an early or mid-career level (e.g., post-doctoral fellow, research associate, assistant professor, associate professor),
• Have interests in Behavioral Science and Cancer-Related Research (e.g., tobacco cessation, obesity, physical activity, diet/nutrition, cancer screening, sun safety, cancer decision making, coping with cancer, cancer survivorship)
• Have not been a PI on a National Institutes of Health R01 funded grant,
• Reside in the United States or U.S. territory, and
• Submit an application with supporting documents
Application Deadline: October 29, 2007, 5:00pm (Eastern Time)
Applications can be obtained at: http://www.scgcorp.com/B_methods/
Note: Twenty-five participants will be selected. Travel and lodging will be sponsored by NCI only for participants who live and work 50 miles or more outside of San Diego, California.
For additional information, contact:
Ms. Debbie Libbey
e-mail: b-methods@scgcorp.com
phone: 301-670-4990
See attachment
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT
A weekly seminar as part of Dr. G. Scott Gazelle's Program in Cancer Outcomes Research Training (PCORT
Initiated in 1987, the Biennial Symposium series provides the stage on which we shine a spotlight on the issue of disproportionate cancer incidence, morbidity and mortality in minority and medically underserved populations in the United States and its associated territories. The Symposium brings together those who represent all aspects and perspectives of the disease in collaboration with the leadership and front-line personnel from the affected communities. Our purpose is to engage in a dialogue that explores issues, finds solutions, and makes recommendations for the various complex problems related to cancer.
At the Symposium, decision makers hear, first-hand, from those directly affected by the problem and the policies that surround cancer. Participants from the communities sit at the discussion table to share the most current research, prevention, and treatment strategies. This unique opportunity creates a dynamic synergy in a setting that respects and celebrates our ethnic and cultural diversity, while recognizing our common humanity and the goal of survivorship. That is what keeps us focused on our mutual enemy - cancer.
For more information:
http://iccnetwork.org/symposium/
11th Biennial Symposium
Baylor College of Medicine
1709 Dryden, Suite 1025
Houston, TX 77030
Tel: 713.798.5383 or toll-free 1.877.BIENNIAL (1.877.243.6642)
Fax: 713.798.6222
E-mail: icc-symposium@bcm.edu
On Friday, March 14, 2008, DF/HCC's Breast Cancer Program in the DF/HCC will sponsor the fifth annual day-long symposium entitled “Breast Cancer Research at Harvard."
The Symposium will be held at the Harvard Club (Commonwealth Ave.) in Boston. We will begin at 8AM with breakfast, will serve lunch, and conclude by 5pm. Advance registration will be required. On February 13, we will email an announcement requesting RSVP’s.
*Seating is limited, and RSVP's are required by Thursday, March 6, 5pm. If you plan to attend, please confirm your attendance to abigail_bird@dfci.harvard.edu so that we can plan accordingly*
The purpose of this retreat is to:
* Engage Breast Cancer Program members to take a more active role, particularly those faculty who have recently joined the program.
* Showcase younger investigators' work - this is an opportunity for graduate students, post-docs and junior faculty.
* We will have presentations and poster sessions, and will publish Abstracts in a booklet entitled "Breast Cancer Research at Harvard", available to all attendees.
We invite all DF/HCC breast cancer researchers to attend, but particularly want to encourage Fellows, Post-docs, and Junior Faculty to submit abstracts.
"Mutations, amplifications, and deletions in human cancer"
Matthew Meyerson, MD, PhD
Dana-Farber Cancer Institute
"Patterns of somatic mutation in human cancer genomes"
Mike Stratton, MD, PhD
Sanger Institute
"Mutational Analyses of Human Cancers: Lessons Learned From Sequencing the Breast and Colorectal Cancer Genomes"
Will Parsons, MD, PhD
Johns Hopkins University
"Molecular markers to guide targeted cancer therapies"
Daniel Haber, MD, PhD
Massachusetts General Hospital
Registration is limited, so please sign up early. To register online, go to:
http://www.dfhcc.harvard.edu/index.php?id=1830
On Friday, April 4, DF/HCC will sponsor an Ovarian Cancer Researchers' Symposium
The Symposium will be held at the Harvard Club (Commonwealth Ave.) in Boston. We will begin at 8AM with breakfast, will serve lunch, and conclude by 3:30pm. Advance registration will be required.
Ursula Matulonis, MD and Planning Committee: Ross Berkowitz, MD, Steve Cannistra, MD, Dan Cramer, MD, Dirk Iglehart, MD, and Carolyn Krasner, MD
The list of abstracts to be presented at the symposium is attached
The agenda for the day is attached
Letrozole Compared with Tamoxifen for Elderly Patients with Endocrine Responsive Early Breast Cancer in BIG 1-98: Efficacy, Treatment, and Adverse Events
Zhuoxin Sun, PhD
Outcomes for Elderly, Advanced-Stage Non-Small Cell Lung Cancer Patients Treated with Bevacizumab in Combination with Carboplatin and Paclitaxel: Analysis of E4599
Suzanne Dahlberg, ScD
Reporting of Subgroup Analyses in Clinical Trials: A Discussion
Steve Lagakos, PhD
Thursday, February 28, 2008 @ 8:30 am
375 Longwood Ave Room 752A/B
Breakfast items will be provided.
Howard Koh, MD, MPH, Leader of the Cancer Disparities program at DF/HCC, will present an overview of Massachusetts Community Network to Eliminate Cancer Disparities Through Education Research and Training (MassCONECT) and discuss issues of working with communities to reduce cancer disparities.
March 6, 2008
4:30-5:30pm
Smith Building, Room 940/946
Dana-Farber Cancer Institute
44 Binney St.
Boston, MA 02115
*Please RSVP to Elizabeth Zdunich at elizabeth_zdunich@dfci.harvard.edu or 617.632.3028
Parking is limited. Please request with your RSVP.
An event at the Broad Institute focused on describing genomic and biomedical advances and research opportunities for minority undergraduate, graduate, and medical school students and scientists. Attendees will have the opportunity to attend talks from leading scientists and network with various types of researchers. Includes afternoon sessions on research opportunities and career development.
The Genomic Revolution in Biomedical Sciences- Minority Research Opportunities
Date: Saturday, February 2, 2008
Time: 9:00 am – 1:30 pm
Location: The Broad Institute of Harvard and MIT
7 Cambridge Center, Cambridge, MA
For directions go to www.broad.mit.edu/info/visiting.html
Registration: There is no charge for the event. We encourage you to register online by Monday, January 28, 2008 at www.broad.mit.edu/diversity/genomicrevolution
Contact: Lucia Vielma at diversity@broad.mit.edu or 617-324-5271.
Agenda: http://www.broad.mit.edu/diversity/genomicrevolution/agenda.html
VASCULAR BIOLOGY SEMINAR
FEBRUARY 28, 2008
SPEAKER: RANDOLPH S. WATNICK, Ph.D.
Assistant Professor, HMS
Department of Surgery, CHB
Boston, MA
TITLE: IDENTIFICATION OF A NOVEL SUPPRESSOR, AND MECHANISM, OF METASTASIS"
ENDERS AUDITORIUM
REFRESHMENTS AVAILABLE AT 4:15 PM
Dr. Carl Wieman will discuss the failures of traditional educational practices, even as used by "very good" teachers, and the successes of some new practices and technology that characterize this more effective approach, and how these results are highly consistent with findings from cognitive science.
Dr. Wieman is a recipient of the Nobel Prize in Physics, the National Science Foundation’s Distinguished Teaching Scholar Award in 2001, the Carnegie Foundation’s U.S. University Professor of the Year Award in 2004, and the American Association of Physics Teachers’ Oersted Medal in 2007. He conducts research on problem-solving skills and student beliefs about physics, and has worked on a variety of research and innovations in teaching physics to a broad range of students.
Event is free and open to the public, but advance registration is requested
The 2/28/08 meeting of the LAM Treatment Alliance Seminar Series will feature Pier Paolo Pandolfi, MD, PhD, who will discuss the research carried out in the Pandolfi laboratory related to the molecular mechanisms and the genetics underlying the pathogenesis of human cancer and the relevance to treating LAM & TSC, as well as on modeling cancer in vivo in model systems. Discussants will lead a provocative conversation focused on therapeutic targets in LAM and TSC and then we will break for dinner and informal networking.
Pier Paolo Pandolfi, MD, PhD – Beth Israel Deaconess Medical Center/ Harvard Medical School
Elizabeth Thiele, MD, PhD – Massachusetts General Hospital/ Herscot Center for TSC/ Harvard Medical School
Brendan Manning, PhD – Harvard School of Public HealthCME credit available. Please RSVP.
Contact: Amy Farber, PhD, amy_farber@hms.harvard.edu
This half-day course is for medical oncologists, otolaryngologists, head and neck surgeons, and other interested clinicians.
Through lecture and discussion attendees will learn about novel agents in thyroid cancer, a new era in induction chemotherapy, and immunotherapy in nasopharyngeal carcinoma. Participants will receive an update on concurrent chemoradiotherapy and hear about recent advancements in managing non-melanoma skin cancer. Registrants will also have an opportunity to participate in a case discussion with a panel of experts.
Registration Fee: $25
If you have any food allergies, or if you require accommodations such as an ASL interpreter, materials in alternative format or wheelchair access, please email kwooten@partners.org or call 1-800-553-3787.
Registration form must be postmarked no later than March 12, 2008.
Please join us at our 2008 Annual Dinner Workshop of the Biostatistics Program of the Dana-Farber/Harvard Cancer Center.
Wednesday, March 12, 2008
6:00-8:30pm
Smith Family Room, Dana 1620, 44 Binney Street, Dana-Farber Cancer Institute
Dinner and dessert will be served.
Please RSVP by Wednesday March 5th to events@jimmy.harvard.edu
or through http://biowww.dfci.harvard.edu/~training/DinnerWorkshop.htm
Challenges in Understanding and Coping with Health Disparities
Speakers:
Glorian Sorensen, MPH, Ph.D.
Professor of Society, Human Development and Health, Harvard School of Public Health,
Director, Center for Community-Based Research, Dana-Farber Cancer Institute
Addressing Disparities in Cancer Risk-Related Behaviors
Efforts to promote cancer prevention rely heavily on our ability to facilitate change in multiple and often interrelated behaviors that have been shown to increase cancer risk. Current epidemiologic evidence links the major behavioral risk factors with a wide range of cancers. Cancer risk-related behaviors are disproportionately concentrated in lower socioeconomic status groups and among some ethnic and racial minorities. There is a persistent need for efficacious and sustainable interventions to promote and maintain healthy behaviors in these populations. This presentation will describe an approach to addressing disparities in risk-related behaviors by attending to social contextual influences such as barriers posed by restricted access to social and material resources, social networks, and cultural and language factors. We tested interventions in two settings, health care clinics and small manufacturing businesses, with the aim of influencing physical activity, red meat consumption, fruit and vegetable consumption, and multivitamin use (for folate), using cluster randomized designs. In Health Centers Study, compared to those in the control group, participants in the intervention health centers made significantly greater improvements in the multiple risk behavior score, as well as in three of the four target risk behaviors: fruit and vegetable consumption,
red meat consumption and multivitamin use. In the Small Business Study, compared to those in control sites, workers in intervention sites also made significantly greater improvements in the multiple risk factor score, as well as in use of multi-vitamins. We also observed that blue-collar workers in the intervention group significantly increased their physical activity. This presentation will also explore the role of social contextual factors in changing one targeted health behavior, fruit and vegetable consumption.
Scarlett Bellamy, Ph.D.
Assistant Professor of Biostatistics, University of Pennsylvania School of Medicine
Design and Analysis Challenges in Dyad-Based Randomized Trials: An
Application to an Ongoing Couple-Based Intervention Trial
Assistant Professor of Biostatistics, University of Pennsylvania School of Medicine
Design and Analysis Challenges in Dyad-Based Randomized Trials: An
Application to an Ongoing Couple-Based Intervention Trial
We start by introducing a subtle challenge for randomizing couple dyads in a group-randomized trial. Specifically, we introduce a modified
block-randomization method when the composition of blocking factors is not known in advance. This approach will be motivated by an ongoing NIMH collaborative research study where the desired goal is to randomize dyads (couples) to one of two interventions, blocking on a dichotomous factor (e.g., HIV sero-status, gender, etc.), but the total number of dyads can not be pre-determined. These settings are further complicated when there are multiple such blocking factors. This talk highlights a practical randomization strategy that ensures the integrity of the randomization process in these settings, as well as presents some preliminary supporting findings. Additionally, we present further analysis challenges which have arisen in the context of this trial.
block-randomization method when the composition of blocking factors is not known in advance. This approach will be motivated by an ongoing NIMH collaborative research study where the desired goal is to randomize dyads (couples) to one of two interventions, blocking on a dichotomous factor (e.g., HIV sero-status, gender, etc.), but the total number of dyads can not be pre-determined. These settings are further complicated when there are multiple such blocking factors. This talk highlights a practical randomization strategy that ensures the integrity of the randomization process in these settings, as well as presents some preliminary supporting findings. Additionally, we present further analysis challenges which have arisen in the context of this trial.
Yi Li, Ph.D.
Assistant Professor of Biostatistics, Dana-Farber Cancer Institute and Harvard School of Public Health
Understand Racial Disparities in Cancer Cures: Results from Large Population Science Studies
Modern cancer treatments have substantially improved cure rates, and have generated a great interest in and need for proper statistical tools to analyze survival data with non-negligible cure fractions as well as to detect racial disparities in cancer cures. However, analysis is often complicated by dependent censoring, which commonly occurs in observational studies when a patient's cause of death is not cancer, but is due to diseases that share the same risk factors with the cancer. In this talk, we report new advances in this field by introducing a more general class of cure models that allow for dependent censoring. We derive the cure models from the perspective of competing risks and model the dependence between the censoring time and the survival time using a class of Archimedean copula models. We apply the mew models to analyze the SEER prostate cancer data. To our knowledge, this is the first study that detected racial disparities in cancer cures from population science perspectives. In particular, this study confirms that the cure fractions for whites are uniformly higher than those for non-whites, even after controlling for the potential complicated dependent censoring mechanisms.
Join us during our monthly Kidney Program/SPORE meeting for presentations from:
Gordon Freeman, M.D. (DFCI) “TIM proteins and phagocytosis of apoptotic cells”
Alexander Guimaraes, M.D. (MGH), “Magnetic Nanoparticle utility in clinical diagnostic staging and preclinical assessment of mTOR inhibition in Renal Cell Cancer”Sanjiv Sam Gambhir, MD, PhD of Stanford University School of Medicine
speaks at the Deloitte Endowed Lecture:
speaks at the Deloitte Endowed Lecture:
"IMAGinING THE FUTURE OF CANCER DIAGNOSIS AND MANAGEMENT"
Thursday, February 28, 2008
Jimmy Fund Auditorium
3-4 pm
Further information contact Melissa Sheehy at (617) 582-7678 or Melissa_Sheehy@dfci.harvard.edu
The National Cancer Institute Office of Biorepositories and Biospecimen Research (OBBR) and the National Institutes of Health Office of Rare Diseases announce the Biospecimen Research Network (BRN) Symposium:
“Advancing Cancer Research Through Biospecimen Science”
March 13–14, 2008
Renaissance M Street Hotel
1143 New Hampshire Avenue NW
Washington, D.C.
The primary goal of the symposium is to address the significant impact of pre-analytical biospecimen variability on cancer research and molecular medicine.
The symposium will feature expert presentations and interactive discussions on topics in biospecimen science including:
• HER2/neu: Lessons Learned
• Access to Existing Knowledge in Biospecimen Science
• Research Advances in Biospecimen Science
• Assessing and Qualifying Biospecimen Quality
• Patient Perspective
• Incorporating Biospecimen Science into Research and Clinical Practice
Key presenters to address the significant impact of biospecimen variability in cancer research and recent advances in biospecimen science include:
• Pat Brown, M.D., Ph.D., Stanford University
• Carolyn C. Compton, M.D., Ph.D., Office of Biorepositories and Biospecimen Research (OBBR), National Cancer Institute
• Angelo deMarzo, M.D., Ph.D., Johns Hopkins University
• Theo deVos, Ph.D., Epigenomics, Inc.
• Steve Gutman, M.D., M.B.A., Food and Drug Administration
• Elizabeth Hammond, M.D., FCAP, University of Utah/LDS Hospital
• Daniel Hayes, M.D., University of Michigan
• Scott Jewell, Ph.D., Ohio State University
• Paula Kim, Translating Research Across Communities (TRACO)
• Lance Liotta, M.D, Ph.D., George Mason University
• Chris Logothetis, M.D., M.D. Anderson Cancer Center
• Scott D. Patterson, Ph.D., Amgen Inc.
• David Ransohoff, M.D., University of North Carolina at Chapel Hill
• Gerry Thomas, Ph.D. Imperial College London, United Kingdom
• Paul Waring, Ph.D., Genentech
• and others
This interactive symposium is free, open to the public and expected to be of particular value to research investigators, clinicians, government representatives, industry representatives, hospital administrators, and patient advocates. For more information, to register, and to submit an abstract, please visit www.brnsymposium.com.
We apologize if you receive more than one copy of this notice. Please share this notice with any interested colleagues. We look forward to your participation. If you have any questions about the meeting or registration, please contact Marlene Goldman at mgoldman@md.capconcorp.com or 301-468-6004 ext. 416.
The National Cancer Institute Office of Biorepositories and Biospecimen Research (OBBR) and the National Institutes of Health Office of Rare Diseases announce the Biospecimen Research Network (BRN) Symposium:
“Advancing Cancer Research Through Biospecimen Science”
March 13–14, 2008
Renaissance M Street Hotel
1143 New Hampshire Avenue NW
Washington, D.C.
The primary goal of the symposium is to address the significant impact of pre-analytical biospecimen variability on cancer research and molecular medicine.
The symposium will feature expert presentations and interactive discussions on topics in biospecimen science including:
• HER2/neu: Lessons Learned
• Access to Existing Knowledge in Biospecimen Science
• Research Advances in Biospecimen Science
• Assessing and Qualifying Biospecimen Quality
• Patient Perspective
• Incorporating Biospecimen Science into Research and Clinical Practice
Key presenters to address the significant impact of biospecimen variability in cancer research and recent advances in biospecimen science include:
• Pat Brown, M.D., Ph.D., Stanford University
• Carolyn C. Compton, M.D., Ph.D., Office of Biorepositories and Biospecimen Research (OBBR), National Cancer Institute
• Angelo deMarzo, M.D., Ph.D., Johns Hopkins University
• Theo deVos, Ph.D., Epigenomics, Inc.
• Steve Gutman, M.D., M.B.A., Food and Drug Administration
• Elizabeth Hammond, M.D., FCAP, University of Utah/LDS Hospital
• Daniel Hayes, M.D., University of Michigan
• Scott Jewell, Ph.D., Ohio State University
• Paula Kim, Translating Research Across Communities (TRACO)
• Lance Liotta, M.D, Ph.D., George Mason University
• Chris Logothetis, M.D., M.D. Anderson Cancer Center
• Scott D. Patterson, Ph.D., Amgen Inc.
• David Ransohoff, M.D., University of North Carolina at Chapel Hill
• Gerry Thomas, Ph.D. Imperial College London, United Kingdom
• Paul Waring, Ph.D., Genentech
• and others
This interactive symposium is free, open to the public and expected to be of particular value to research investigators, clinicians, government representatives, industry representatives, hospital administrators, and patient advocates. For more information, to register, and to submit an abstract, please visit www.brnsymposium.com.
We apologize if you receive more than one copy of this notice. Please share this notice with any interested colleagues. We look forward to your participation. If you have any questions about the meeting or registration, please contact Marlene Goldman at mgoldman@md.capconcorp.com or 301-468-6004 ext. 416.
The New York Academy of Sciences will be hosting 1-day conference called “Targeted Therapies for Gastrointestinal Cancer” on March 14, at the downtown New York City location.
The goal of this conference is to provide a highly educational agenda and exciting networking opportunities for physicians, scientists, and other industry professionals working in the field of colorectal cancer. The program features sessions on breakthroughs in the identification of colorectal cancer biomarkers, the discovery of drug targets, and new targeted therapies.
A special discount for multiple registrations is now being offered: register 2 and get the 3rd registration free.
The 6th annual International Symposium on Targeted Anticancer Therapies (TAT) is being held in Bethesda, Maryland, March 20-22. Interested investigators may register on the TAT website . Additional background information on the symposium from the TAT 2008 Secretariat is included below.
Abstract Submission
March 8, 2008. Regular online abstract submission for TAT 2008 is closed, but investigators wishing to submit a late-breaking abstract should contact the TAT 2008 Congress Director, Marinus W. Lobbezoo, Ph.D., via email at lobbezoo@mccm.nl, attaching the complete abstract in Word format. The Program Committee will then organize a rapid round of expert review and provide scheduling details within 3-4 days (if the abstract content qualifies for a late-breaking paper). Late-breaking abstracts will be taken into consideration if submitted before or on March 8. If accepted for presentation, late-breaking abstracts will be included in the meeting supplement to Annals of Oncology.
NCI and ESMO, partners in TAT 2008
TAT 2008 is organized by the NDDO Research Foundation in partnerships with the U.S. National Cancer Institute (NCI) and the European Society for Medical Oncology (ESMO). All accepted abstracts will be published in a supplement to Annals of Oncology, the official journal of ESMO.
Scope and content
The scientific program of TAT 2008 will cover many types of targets and new drugs in early-phase clinical development, and will focus on clinical and translational research. The 2008 program will also cover clinical trials of combinations of targeted agents which are being conducted in increasing numbers. TAT 2008 will thus provide a glimpse of the future of cancer therapy. A recent update of the program is available on the TAT 2008 website.
Plenary session themes included in TAT 2008:
Combinations of targeted agents in early clinical trial
Insulin-like growth factor receptor inhibitors
Hsp90 inhibitors
Cancer stem cell drug targets
Poly (ADP-ribose) polymerase (PARP) as a drug target
Immunotherapy of cancer
Inhibitors of PI3K-mTOR signaling
C-Met as drug target
Intracellular drug targets (including JAK2, MEK, HIF, and aurora kinases)
Methodological and regulatory issues
Keynotes will address:
The proteasome as a drug target
Targeted agents in multiple myeloma,
Angiogenesis inhibitors in new and emerging indications
BOSS presents – (DFCI Smith 308/309)
Antonio Wolf, MD – Assistant Professor of Oncology – Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
“Controversies and Challenges in HER2 Testing"
Antonio Wolf, MD – Assistant Professor of Oncology – Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
“Controversies and Challenges in HER2 Testing"
Biomedical Science Careers Student Conference
The Boston Park Plaza Hotel
Friday evening, April 4 and Saturday, April 5, 2008
The Boston Park Plaza Hotel
Friday evening, April 4 and Saturday, April 5, 2008
On behalf of the Biomedical Science Careers Program (BSCP), we wish to invite you to join us for the ninth biennial New England-wide BIOMEDICAL SCIENCE CAREERS STUDENT CONFERENCE for postdoctoral fellows; medical, dental and graduate students; post-baccalaureates; college and community college students; and high school seniors and juniors.
The conference will take place at The Boston Park Plaza Hotel in Boston, Massachusetts on Saturday, April 5, 2008 from 7:30 AM to 6:00 PM. All postdoctoral fellows, medical, dental, graduate and out-of-town post-baccalaureates, college and community college students are also welcome to join us (pre-registration required) on Friday evening, April 4, for dinner and keynote address. Dinner will be followed by interactive workshops.
A tentative agenda is attached here.
There is no registration fee for the conference but pre-registration is required. If you want to receive application form, tentative agenda and further information, please email us your current postal mailing address as soon as possible.
Fahri Ercem
Program Coordinator
Biomedical Science Careers Program
c/o Harvard Medical School
164 Longwood Avenue, 2nd Floor
Boston, MA 02115-5818
Phone: 617-432-2729
Fax: 617-432-3834
Email: fahri_ercem@hms.harvard.edu
www.bscp.org
Broadcast Friday, February 29, 2008 at 2:00pm-3:30pm EST
The 10th Annual William T. Small, Jr. Keynote Lecture: "The Science and Epidemiology of Racism and Health in the United States: an Ecosocial Perspective", by Nancy Krieger, Ph.D., Harvard School of Public Health
The Lecture is the highlight of the 29th Annual UNC School of Public Health Minority Health Conference on “The Impact of Poverty, Culture, and Environment on Minority Health”, presented by the School's Minority Student Caucus, from 8:30am-4:30pm on February 29. The broadcast of the Keynote Lecture will include a live call-in question-and-answer session with Dr. Krieger, moderated by Adaora Adimora, MD, MPH.
For information about the Conference and the broadcast please visit www.minority.unc.edu/sph/minconf/2008/
(Note that only the Keynote Lecture will be broadcast.)
- Satellite broadcast information: www.minority.unc.edu/sph/minconf/2008/satellite/
- Webcast information: www.minority.unc.edu/sph/minconf/2008/webcast/
- Online registration form to attend the entire conference (in person): https://oce.sph.unc.edu/forms/mhc/
(if you wish to attend in person, don't put off registering - the conference fills up early!
- Read viewer comments from last year's broadcast: www.minority.unc.edu/sph/minconf/2007/webcast/WTSjrKeynoteComments2007.htm
- Other attractions:"Does Racism Make Us Sick?" (with Drs. Karina Walters, Gilbert Gee, Luisa Borrell, David Williams)
- Agenda and slides: http://www.minority.unc.edu/institute/2007/agenda.cfm
- Archived webcast (no charge): http://www.minority.unc.edu/resources/webcasts/webregist.cfm?speaker=racismsick&event=SPHRIMH&year=2007
Archived webcasts of past William T. Small, Jr. Keynote Lectures by Drs. Sherman James, Camara Jones, Mary Northridge, Henry Lewis Taylor, Jr., Meredith Minkler, and David Malebranche as well as selected presentations from the Annual Summer Public Health Research Videoconference on Minority Health are available on our website (www.minority.unc.edu/resources/webcasts/).
VHS tapes are available for purchase from the Public Health Foundation (bookstore.phf.org).
A catalog of past Minority Health Project broadcasts is under construction at www.minority.unc.edu/resources/catalog/
Wednesday, March 12, 2008
12:30-2:00 pm
World Health/Leadership Forum “Perspectives on Caribbean Health”
Presentation with Reception and Discussion to follow.
Presenters: The Honorable Leslie Ramsammy, Minister of Health, Guyana AND
Dr. Bernadette Theodore Gandi, Caribbean Program Coordinator, The Pan American Health Organization (PAHO)
Location: Harvard Medical School, Waterhouse Room, Gordon Hall
Hosted by Harvard Medical School Office for Diversity and Community Partnership
For more information contact Kelly Jo Cigman at (617) 432-2645 or kellyjo_cigman@hms.harvard.edu
In support of Patient Safety Awareness Week, Jim Conway will deliver a keynote address focusing on issues pertaining to:
- Recent lessons about patient safety
- Growing need for improvement
- Choosing methods to achieve your goals
- Impact of Dana-Farber's leadership
VASCULAR BIOLOGY SEMINAR
MARCH 6, 2008
BETH L. ROMAN, Ph.D.
Assistant Professor, Dept. of Biological Sciences
University of Pittsburgh, Pittsburgh, PA
"HOW TO MAKE AN ARTERIOVENOUS MALFORMATION: INSIGHTS FROM ZEBRAFISH"
4:30 PM @ ENDERS AUDITORIUM
REFRESHMENTS AVAILABLE AT 4:15 PM
VASCULAR BIOLOGY SEMINAR
THURSDAY, MARCH 20, 2008
SPEAKER: CHARLOTTE KUPERWASSER, Ph.D.
Assistant Professor, Dept. of Anatomy & Cellular Biology
Investigator, Department of Radiation Oncology/MORI
Tufts University School of Medicine
Boston, MA
TITLE: "SYSTEMIC ANGIOGENESIS AND BONE MARROW RECRUITMENT: A NOVEL MECHANISM FOR ESTROGEN IN CANCER PATHOGENESIS"
Dana-Farber Cancer Institute and DFHCC Seminars in Oncology
“Calcium Signalling and Gene Regulation in Lymphocytes”
Anjana Rao, Ph.D.
Professor of Pathology,
Harvard Medical School,
Senior Investigator,
Immune Disease Institute,
Boston, MA
Tuesday February 26th 2008
4:00pm
Jimmy Fund Auditorium
Host: Myles A. Brown, M.D.
DFCI Tel: 617-632-4750
“Calcium Signalling and Gene Regulation in Lymphocytes”
Anjana Rao, Ph.D.
Professor of Pathology,
Harvard Medical School,
Senior Investigator,
Immune Disease Institute,
Boston, MA
Tuesday February 26th 2008
4:00pm
Jimmy Fund Auditorium
Host: Myles A. Brown, M.D.
DFCI Tel: 617-632-4750
This meeting will require videoconferencing with colleagues at the Dana-Farber.
“Quality of Life and End-of-Life in Heart Disease”
BWH - Cardiovascular Division
All faculty and staff of the Division of Hematology are encouraged to attend.
“Targeting Tumor Microenvironment to Treat Cancer: Bench-to-Bedside and Back”
Rakesh K. Jain, Ph.D.
Director, Edwin L. Steele Laboratory for Tumor Biology
Video Conference to Simches Building
Elkan Halpern, Ph.D., Chief Statistician, Department of Radiology
Director of Statistics, Institute of Technology Assessment
Wednesdays, February 27 & March 5, 12 & 19,
Registration is Required
Basic Science Presents:
“Novel Genetic Screens to Study Cancer and Human Disease”
Joseph Pearlberg, M.D., Ph.D.
Department of Biological Chemistry and Molecular Biology
Harvard Medical School
“Novel Genetic Screens to Study Cancer and Human Disease”
Joseph Pearlberg, M.D., Ph.D.
Department of Biological Chemistry and Molecular Biology
Harvard Medical School
Registration is required.
Are you involved in research billing for clinical trials for your department? Doug Reichgott, Assoc. Director of Clinical Research Financial Services of Partners and Sonya D. Huggins, Research Compliance for Brigham & Women's hospital are presenting a comprehensive overview of proper research billing at BWH.
Are you involved in research billing for clinical trials for your department? Doug Reichgott, Assoc. Director of Clinical Research Financial Services of Partners and Sonya D. Huggins, Research Compliance for Brigham & Women's hospital are presenting a comprehensive overview of proper research billing at BWH.
"The Cancer Experience from A Patient's Perspective"
David E. Fisher, MD, PhD
The Fisher laboratory studies molecular mechanisms regulating gene expression and development as a means of understanding cancer biology and devising novel approaches to prevention, diagnosis, and treatment.
The Fisher laboratory studies molecular mechanisms regulating gene expression and development as a means of understanding cancer biology and devising novel approaches to prevention, diagnosis, and treatment.
The 3/13/08 meeting of the LAM Treatment Alliance Seminar Series will feature David E. Fisher, MD, PhD. The Fisher laboratory studies molecular mechanisms regulating gene expression and development as a means of understanding cancer biology and devising novel approaches to prevention, diagnosis, and treatment. Research projects focus largely on the biology of melanocytes (pigment cells), the cells of origin of malignant melanoma, which is one of the most aggressive and treatment-resistant cancers in humans.
LAM cells stain positive for melanocytic markers which leads us to ask critical questions about what we can learn from this field to help us to effectively treat LAM & TSC. Discussant and commentator will lead a provocative conversation about the talk’s implications for treatment and then we will break for dinner and informal networking.
David E. Fisher, MD, PhD – Dana Farber Cancer Institute/ Harvard Medical School Elizabeth Henske, MD – Fox Chase Cancer Center Andrew Wagner, MD, PhD – Dana Farber Cancer Institute/ Harvard Medical School
CME credit available. Please RSVP
Contact: Amy Farber, PhD, amy_farber@hms.harvard.edu
A special seminar hosted by the DFCI Center for Cancer Systems Biology (CCSB), the Department of Cancer Biology, DFCI and the Department of Genetics, HMS
A special seminar hosted by the DFCI Center for Cancer Systems Biology (CCSB), the Department of Cancer Biology, DFCi and the Department of Genetics, HMS
"Systems Approach to Drug Development and Implementation" - Dr. Mills will discuss studies involving Reverse Phase Protein Arrays to monitor pathway activation together with other molecular analyses of tumor cells and patient outcome.
VASCULAR BIOLOGY SEMINAR
THURSDAY, MARCH 13, 2008
SPEAKER: MARK W. KIERAN, M.D., Ph.D.
Director, Pediatric Medical Neuro-Oncology
Dana-Farber Cancer Institute
Division of Pediatric Hematology/Oncology
Boston, MA
TITLE: "TARGETING THE TUMOR MICROENVIORNMENT: FROM CAGE TO CLINIC"
ENDERS AUDITORIUM @ CHILDREN'S HOSPITAL
4:30 P.M.
Refreshments available @ 4:15 PM
VASCULAR BIOLOGY SEMINAR
THURSDAY, MARCH 27, 2008
SPEAKER: RYAN J. WATTS, Ph.D.
Scientist, Group Leader
Neurodegeneration Labs, Department of Neurobiology
Genentech, Inc.
So. San Francisco, CA
TITLE: "GUIDING BLOOD VESSELS: NEUROPILIN'S ROLE IN DEVELOPMENT"
ENDERS AUDITORIUM AT CHILDREN'S HOSPITAL
4:30 PM
REFRESHMENTS AVAILABLE AT 4:15 PM.
"Systems Approach to Drug Development and Implementation" - Dr. Mills will discuss studies involving Reverse Phase Protein Arrays to monitor pathway activation together with other molecular analyses of tumor cells and patient outcome.
Monitor Transcript or Exon Level Expression in Whole Blood, FFPE, LCM, sorted cells, embryonic structures, and degraded samples.
Local Sponsor: Towia Liberman, Ph.D, Director of BIDMC Genomics Center
Co Presenters: Travis Burleson, Field Application Specialist, Affymetrix, Inc. and John Smutko National Service Manager, NuGen Technologies, Inc.
Cancer as a problem of tissue organization. Marcel Maffini, Tufta University
Paul Hergenrother
University of Illinois
Controlling Bacterial and Cancer Cell Death with Small Molecules
Howard Koh, MD, MPH, Leader of the Cancer Disparities program at Dana-Farber/Harvard Cancer Center, will present an overview of Massachusetts Community Network to Eliminate Cancer Disparities Through Education Research and Training (MassCONECT) and discuss issues of working with communities to reduce cancer disparities.
RSVP by e-mail or call: 617.632.3028.
RSVP by e-mail or call: 617.632.3028.
The Department of Cancer Biology, DFCI and the Department of Pathology, HMS present a special seminar:
"O-GlcNAc, nutrient sensing, diabetes"
presented by Xiaoyong Yang, PhD
The Salk Institute
La Jolla, California
Hosted by Bruce Spiegelman, DFCI
Dana-Farber Cancer Institute and DFHCC Seminars in Oncology presents: Signaling through the Ubiquitin-Proteasome Pathway
Wade Harper, Ph.D.
Professor of Pathology,
Harvard Medical School,
Boston, MA
Host: Host: Myles A. Brown, M.D.
Charles Balch, M.D.
Professor of Surgery and Oncology
Johns Hopkins Medical Institutions
Baltimore, Maryland
“Melanoma as an example of evidence-based medicine"
Light refreshments will be served prior to Dr. Balch’s lecture starting at 8:30am.
Also a Partners or Harvard ID is necessary for entrance into the Simches Conference Center, if you need access please contact Brie Trefrey , Btrefrey@partners.org
Regulatory Mechanisms in Development and Disease.
Juliana Brown (Jackson-Grusby Lab)
"Epigenetic regulation in cancer stem cells in a mouse brain tumor model"
Light Refreshments available beginning at 3:45pm
Presented by:
Saul Rosenberg, PhD Senior Director Discovery
Gary Gordon MD, PhD: Divisional Vice President Pharmaceutical Development
TOPICS/PRODUCTS TO BE PRESENTED:
ABT-869, a small molecule receptor tyrosine kinase inhibitor of VEGF&PDGF
ABT-263, a small molecule inhibitor of BCL-2 family of proteins
ABT-888, a small molecule inhibitor of PARP (poly ADP-ribose polymerase)
If you would like to schedule a 1:1 meeting with the Abbott representatives for the afternoon of March 20th, please contact Petra Loesch at 617-724-3867 (ploesch@partners.org).
PARKING: Please park in DFCI’s Smith Garage at One Jimmy Fund Way.
DFCI will validate parking for the event.
The Center for Cancer Systems Biology at DFCI (CCSB), the DFCI Department of Cancer Biology and the HMS Department of Genetics present a special seminar:
Structure and Function of a Transcriptional Network Activated by the Kinase Hog1
Presented by Andrew Capaldi, PhD, FAS Center for Systems Biology, Harvard University
Hosted by Marc Vidal, PhD
Racial and Ethnic Disparities: Keeping Current Seminar Series
This series features informative presentations from experts in the field; context, perspectives and opinions from key health care stakeholders; and opportunity for discussion from all participants. All series events are free and open to the public.
The next event will be held from Noon to 1PM on Wednesday, March 26th, 2008, and the featured topic will be disparities in the ED. Dr. Andrew Wilper will present his paper "Waits To See An Emergency Department Physician: U.S. Trends And Predictors, 1997-2004."
This event will be held in the Trustees Room at Massachusetts General Hospital and members of local health care and research communities are encouraged to attend.
Lunch will be served. RSVP to reserve your spot: disparitiessolutions@partners.org
"Childhood muscle cancer: Cell of origin and therapeutic targets"
Guest Speaker:
Charles Keller, MD
The University of Texas Health Science Center
Speaker: H. Gilbert Welsch, MD, MPH
VA Outcomes Group
Department of Veterans’ Affairs
White River Junction, VT
VA Outcomes Group
Department of Veterans’ Affairs
White River Junction, VT
A special seminar presented by the Department of Cancer Biology (DFCI) and the Department of Pathology (HMS)
How does the hypothalamus sense overnutrition and cause diseases?
Dongsheng Cai, MD, PhD
University of Wisconsin - Madison
Hosted by Bruce Spiegelman, PhD
A special seminar presented by the Center for Cancer Systems Biology (CCSB), the Department of Cancer Biology (DFCI) and the Department of Genetics (HMS)
Genetic Network Dysregulation and Human Disease: Results from Quantitative Systems Biology
Alberto Polleri, PhD
Stanford University School of Medicine
Hosted by Marc Vidal, PhD
A special seminar presented by the Department of Pediatric Oncology (DFCI) and the Department of Neurobiology (HMS)
Neural Stem Cells, Epigenetics and Gene Therapy of Neurological Disorders
Mojgan Rastegar, PhD
Hospital for Sick Children, Toronto
Hosted by Rosalind Segal, MD, PhD
“Integrity: What Elliott Spitzer Could Learn From Genomes”
Douglas E. Koshland, Ph.D.
Investigator HHMI and
Senior Staff Member
Department of Embryology,
Carnegie Institution,
Baltimore, MD
Tuesday March 25th 2008 4:00pm
Jimmy Fund Auditorium
Host: David Pellman, M.D.
DFCI Tel: 617 632-2072
Douglas E. Koshland, Ph.D.
Investigator HHMI and
Senior Staff Member
Department of Embryology,
Carnegie Institution,
Baltimore, MD
Tuesday March 25th 2008 4:00pm
Jimmy Fund Auditorium
Host: David Pellman, M.D.
DFCI Tel: 617 632-2072
PROGRAM IN CANCER IMMUNOLOGY SEMINAR SERIES
"Focal Adhesion Kinase (FAK) function in normal and leukemic progenitor B cells"
Leslie Silberstein, MD
Director, Joint Program in Transfusion Medicine
Children's Hospital Boston, Dana-Farber Cancer Institute
& Brigham and Women's Hospital
Thursday, March 20th, 2008
3:30 PM
SMITH 308-309
Is there the Courage to Change the American Diet?
Kelly Brownell, PhD
Professor of Psychology, Epidemiology and Public Health
Director, Rudd Center for Food Policy and Obesity
Yale University
Monday, March 31 @ 12:30pm in Kresge G1
Cancer Prevention Dialogues are co-hosted by the Dana Farber/Harvard Cancer Center.
A Talk by Dr. Alan M. Krensky
NIH Deputy Director for the Office of Portfolio Analysis and Strategic Initiatives
Wednesday, April 2, 2008 at 4:00 P.M.
Broad Institute Audiotorium
7 Cambridge Center
Cambridge, MA 02139
T lymphocytes are central effectors and regulators of the immune response. Dr. Krensky will discuss two molecules that he first identified in human organ transplant rejection but that are now known to be important in the three major infections of mankind: tuberculosis, malaria and AIDS. RANTES, a chemoattractant cytokine, or "chemokine" attracts cells to sites of inflammation. Its receptor, CCR5, is a mode of entry for HIV to enter immune cells. Therefore RANTES and CCR5 are important targets for potential AIDS therapeutics. Granulysin, a cytolytic molecule, is present in cytolytic T lymphocytes and natural killer cells, and kills mycobacteria tuberculosis and plasmodium falciparum, as well as other microbes (bacteria, fungi and parasites) and tumor cells. Small synthetic peptides of granulysin are being developed as new antibiotics. The journey from first discovery to development as potential therapeutics for major diseases of mankind will be described.
***Dr. Krensky is in charge of the NIH Roadmap for Medical Research; he will also be discussing this program in addition to his scientific presentation***
Dr. Krensky is the first Director of the Office of Portfolio Analysis and Strategic Initiatives (OPASI) and a Deputy Director of the National Institutes of Health. For the past 23 years, he was at Stanford University where he served as the Shelagh Galligan Professor of Pediatrics, Associate Dean for Children's Health, Associate Chair for Research, Chief of the Division of Immunology and Transplantation Biology and Executive Director of the Children's Health Initiative. A medical graduate of the University of Pennsylvania in 1977, he trained in pediatrics and nephrology at Boston Children's Hospital and immunology with Steven Burakoff at the Dana-Farber Cancer Institute. After one year on the faculty at Harvard, he moved to Stanford as Assistant Professor of Pediatrics in 1984. He was appointed Shelagh Galligan Professor in 1995 and has been at NIH since July 8, 2007.
The seminar is open to the public, but due to limited seating, please register by e-mailing cancer@mit.edu with "Krensky seminar" in the Subject line
***Dr. Krensky is in charge of the NIH Roadmap for Medical Research; he will also be discussing this program in addition to his scientific presentation***
Dr. Krensky is the first Director of the Office of Portfolio Analysis and Strategic Initiatives (OPASI) and a Deputy Director of the National Institutes of Health. For the past 23 years, he was at Stanford University where he served as the Shelagh Galligan Professor of Pediatrics, Associate Dean for Children's Health, Associate Chair for Research, Chief of the Division of Immunology and Transplantation Biology and Executive Director of the Children's Health Initiative. A medical graduate of the University of Pennsylvania in 1977, he trained in pediatrics and nephrology at Boston Children's Hospital and immunology with Steven Burakoff at the Dana-Farber Cancer Institute. After one year on the faculty at Harvard, he moved to Stanford as Assistant Professor of Pediatrics in 1984. He was appointed Shelagh Galligan Professor in 1995 and has been at NIH since July 8, 2007.
The seminar is open to the public, but due to limited seating, please register by e-mailing cancer@mit.edu with "Krensky seminar" in the Subject line
For further information, contact Mary Heckbert
Office of the Executive Director
Koch Institute for Integrative Cancer Research at MIT
617-324-2169
Harvard Medical School Office for Diversity and Community Partnership is pleased to announce the 2008 ALVIN F. POUSSAINT, MD, VISITING LECTURESHIP
“Racial and Ethnic Disparities: Institutional Responses, Personal Reflections”
This year's lecturer is M. Roy Wilson, MD, MS, the Chancellor of the University of Colorado Denver, and a graduate of the HMS Class of 1980. He performed both his ophthalmology residency and glaucoma fellowship at the Massachusetts Eye and Ear Infirmary. Dr. Wilson is an ophthalmologist whose scientific contributions have bridged the fields of ophthalmology and epidemiology. He is also a former medical school dean.
RSVP to Althea Roach Thomas at 617-432-0161 or althea_roachthomas@hms.harvard.edu
Monday, March 31, 2008
5:00 - 6:00 pm
The Waterhouse Room
Gordon Hall of Medicine
25 Shattuck Street
Boston, MA 02115
Join Dr. Nancy Krieger and the Public Health Intersections with Politics group for the screening and discussion of...
UNNATURAL CAUSES: Is Inequality Making Us Sick?
A PBS documentary series a exploring racial and socioeconomic inequities in health in the U.S.
****STARRING****
Nancy Krieger, David Williams, Ichiro Kawachi, Jack Shonkoff and Jim Yong Kim!
Premier Screening of UNNATURAL CAUSES at the Harvard School of Public Health
When: Thursday, April 3rd from 8:00-11:00 pm
Where: Room 110 (Dean's room), Kresge and cafeteria
Harvard School of Public Health (677 Huntington)
8:00 - 8:30: Refreshments
8:30 - 9:30: Episode 1: "In Sickness and in Wealth"
9:30 - 10:00: discussion with Dr. Nancy Krieger (& more refreshments)
10:00 - 11:00: Episode 2 (live on TV): "When the Bough Breaks" & "Becoming American"
Through this screening, organizers and attendees will hope to spark discussion to increase public awareness of the alarming socio-economic and racial disparities in health and their human and financial costs as well as inject considerations of social and economic policy into future discussions on health.
FOR RSVP and questions: ndhavan@hsph.harvard.edu
Sponsored by HSPH Public Health Intersections with Politics (PHIP) Student Group and the Center for Society and Health
http://www.pbs.org/unnaturalcauses/
Clinical and Translational Research and the NIH Roadmap
presented by
Alan M. Krensky, M.D.
NIH Deputy Director for the Office of Portfolio Analysis and Strategic Initiatives (OPASI)*
Wednesday, April 2
4:00 p.m.-5:00 p.m.
Broad Institute Auditorium, 7 Cambridge Center, Cambridge, MA 02142
presented by
Alan M. Krensky, M.D.
NIH Deputy Director for the Office of Portfolio Analysis and Strategic Initiatives (OPASI)*
Wednesday, April 2
4:00 p.m.-5:00 p.m.
Broad Institute Auditorium, 7 Cambridge Center, Cambridge, MA 02142
Dr. Krensky will discuss the
1) the Office of Portfolio Analysis and Strategic Initiatives at NIH;
2) Networks, Clinical and Translational Science and Immune Tolerance; and
3) Dichotomies, Biology/Medicine, Discovery/Cure, and Evidence-based/Personalized Medicine. These activities and concepts are transforming the way we do biomedical science and may
impact American competitiveness in a "flat" world.
The seminar is open to the public, but due to limited seating, please register by e-mailing lubien@mit.edu with "Krensky seminar" in the Subject line
Speaker: Eunyoung Cho, Sc.D. (BWH)
“Analgesic Use and Risk of Kidney Cancer in Population Studies ”
Speaker: Irving Kaplan, M.D. (BIDMC)
“CyberKnife Hypofractionate Radiosurgery for Renal Cancer ”
Dana-Farber/Harvard Cancer Center
A Comprehensive Cancer CenterDesignated by the National Cancer Institute